Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Status
- COMPLETED
- Phase
- PHASE3
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
neoadjuvant_thymic Epithelial Tumor
- Status
- UNKNOWN
- Phase
- PHASE2
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
- Status
- TERMINATED
- Phase
- PHASE1